human
rhinovirus
rv
small
nm
nonenvelop
ssrna
virus
picornavirida
famili
strain
rv
identifi
classifi
three
genet
clade
b
c
accord
sequenc
similar
competit
assay
cellular
bind
site
group
rv
major
group
minor
group
virus
depend
use
ldlr
receptor
recent
asthma
suscept
gene
product
shown
mediat
rvc
bind
replic
rv
infect
mainli
transmit
due
direct
contact
via
fomit
inocul
eye
nose
fingertip
rv
predominantli
infect
cell
upper
respiratori
tract
although
rv
rna
also
found
lower
airway
experiment
rv
infect
situ
hybrid
experi
shown
rv
initi
replic
small
group
airway
epitheli
cell
without
induct
visibl
cytopath
effect
cell
destruct
rv
infect
howev
compromis
epitheli
barrier
integr
may
caus
increas
transloc
pathogen
complic
respiratori
diseas
rv
etiolog
agent
onehalf
twothird
common
cold
children
infect
per
year
adult
infect
per
year
peak
infect
occur
throughout
year
mild
selflimit
immunocompet
host
rv
infect
associ
bronchiol
infant
pneumonia
immunosuppress
exacerb
preexist
pulmonari
condit
asthma
chronic
obstruct
pulmonari
diseas
furthermor
children
experi
wheez
result
rv
infect
increas
risk
subsequ
develop
asthma
mani
condit
requir
hospit
place
signific
econom
cost
upon
healthcar
infrastructur
antigen
divers
display
larg
varieti
rv
serotyp
pose
signific
challeng
research
effect
univers
rv
vaccin
current
excess
ten
clinic
trial
current
ongo
usa
alon
attempt
develop
effect
prevent
vaccin
infect
fact
around
rv
serotyp
bind
human
bind
murin
receptor
past
limit
avail
valid
anim
model
infect
howev
develop
mousehuman
chimera
mous
model
studi
exacerb
induc
human
rv
togeth
avail
human
experiment
infect
provid
avenu
toward
develop
better
therapeut
addit
signific
morbid
associ
econom
cost
attribut
rv
infect
would
lend
weight
global
effort
full
character
differ
rv
strain
thu
develop
effect
antivir
widest
possibl
number
rv
serotyp
urgent
requir
number
establish
chemotherapeut
option
viral
infect
still
rel
low
studi
undertaken
view
character
antirv
activ
drug
alreadi
licens
use
infect
excess
antivir
drug
use
medic
treatment
viral
infect
categor
function
group
review
viral
infect
antivir
treatment
option
includ
hiv
hepat
b
c
viru
herpesviru
influenza
viru
human
cytomegaloviru
varicellazost
viru
respiratori
syncyti
viru
rsv
human
papillomaviru
none
drug
licens
use
rv
infect
number
exist
therapeut
demonstr
antivir
activ
number
rv
serotyp
thu
excit
prospect
therapeut
use
infect
ribavirin
synthet
guanosin
nucleosid
interfer
synthesi
viral
mrna
frequent
use
effect
therapeut
combin
pegyl
treatment
hepat
c
infect
also
use
individu
clinician
treatment
sever
lower
respiratori
tract
infect
caus
rsv
infect
caus
respiratori
pathogen
adenoviru
also
treat
ribavirin
normal
patient
immunocompromis
receiv
bone
marrow
stem
cell
transplant
coronavirus
associ
sever
acut
respiratori
syndrom
sarscov
middl
east
respiratori
syndrom
also
studi
context
ribivirin
therapi
although
outcom
mix
conjunct
therapi
pegyl
suggest
addit
ribavirin
also
util
treatment
sever
viral
hemorrhag
fever
caus
pathogen
hantaviru
lassa
viru
also
treatment
nairoviru
caus
tickborn
diseas
hemorrhag
fever
howev
drug
report
activ
marburg
viru
ebola
viru
dengu
viru
appear
limit
activ
hsv
hiv
context
rv
infect
ribavirin
number
modifi
analog
shown
moder
antivir
activ
also
report
moder
suscept
treatment
although
vitro
studi
use
altern
serotyp
rv
suggest
ribavirin
rel
ineffect
howev
clinic
report
ribavirin
therapi
twin
use
indic
combinatori
therapi
could
valu
patient
reportedli
exhibit
enhanc
clearanc
rv
infect
follow
treatment
two
compound
number
studi
focus
upon
effect
compound
pleconaril
human
rv
pleconaril
propyl
phenyl
trifluoromethyl
known
display
broad
spectrum
antivir
activ
rang
viral
pathogen
known
bind
hydrophob
pocket
within
viral
capsid
alter
bind
viral
pathogen
host
cell
receptor
block
uncoat
rv
other
believ
take
place
protein
largest
expos
surfac
protein
capsid
one
comprehens
studi
examin
effect
pleconaril
select
five
rv
serotyp
rvhank
later
serotyp
clinic
isol
use
vitro
cytopath
effect
cpe
inhibit
assay
studi
demonstr
compound
effect
antivir
activ
five
serotyp
median
major
untyp
clinic
isol
two
separ
studi
also
demonstr
find
accord
show
antivir
activ
pleconaril
interestingli
analysi
sever
rv
serotyp
also
assess
structur
featur
amino
acid
make
protein
identifi
sever
common
sequenc
mutat
confer
natur
resist
capsid
bind
compound
pleconaril
well
could
aris
result
antivir
drug
treatment
number
human
experiment
pleconaril
administr
studi
found
pleconaril
could
offer
tangibl
treatment
option
rv
infect
volunt
treat
drug
appear
show
less
clinic
symptomolog
lower
recoveri
picornavirus
control
howev
vari
viru
serotyp
suscept
pleconaril
appear
play
signific
role
efficaci
treatment
clinic
outcom
howev
studi
pleconaril
analog
enhanc
activ
rv
still
ongo
number
novel
capsid
bind
compound
shown
effect
antivir
activ
rhinoviru
anoth
capsid
bind
protein
gener
intens
interest
pirodavir
studi
compound
show
show
antivir
activ
comprehens
assess
undertaken
brown
et
al
establish
pirodavir
substanti
antivir
activ
rang
differ
serotyp
rv
interestingli
appear
complet
resist
compound
howev
studi
seri
pyridazinylpiperidinylbas
compound
synthes
one
deriv
also
found
particularli
effect
number
rv
serotyp
similar
context
analog
pirodavir
term
also
shown
effect
activ
sever
rv
serotyp
assess
phase
ii
clinic
trial
anoth
capsid
bind
drug
vapendavir
shown
inhibit
recent
also
util
phase
ii
clinic
trial
time
write
efficaci
treatment
yet
unclear
compound
rupintrivir
also
known
inhibitor
viral
proteas
enzym
viral
encod
essenti
rv
replic
studi
rupintrivir
context
rv
infect
reveal
exhibit
moder
antivir
activ
vitro
rang
rv
serotyp
coxsackieviru
addit
demonstr
efficaci
phase
ii
clinic
trial
experiment
rv
infect
well
toler
human
subject
multipl
human
exposur
interestingli
recent
studi
also
reveal
analog
rupintrivir
base
prolin
azetidin
modif
compound
also
reveal
broad
spectrum
activ
rang
rv
serotyp
interest
observ
rupintrivir
also
exhibit
vitro
activ
newli
discov
human
rv
c
strain
assess
potenti
rv
evolv
resist
rupintrivir
also
conduct
select
novel
rv
variant
increas
concentr
drug
display
minim
moder
suscept
reduct
collect
clear
compound
novel
analog
potenti
develop
novel
therapeut
rv
vivo
trial
requir
literatur
review
also
identifi
number
small
compound
investig
novel
inhibitor
rv
past
four
decad
includ
compound
show
antivir
activ
rv
viral
pathogen
studi
identifi
novel
biphenyloxi
propyl
isoxazol
deriv
activ
recent
report
describ
seri
benzothiophen
deriv
inhibit
replic
number
rv
serotyp
propos
act
viral
capsid
bind
similar
way
pleconaril
recent
three
novel
epidithiodiketopiperazin
synthes
display
activ
interestingli
antifung
compound
itraconozol
recent
found
vitro
vivo
antivir
activ
rv
infect
potenti
due
inhibit
cellular
cholesterol
traffick
process
author
suggest
accord
anoth
studi
essenti
rv
replic
activ
retain
assess
antivir
activ
itraconozoleload
microemuls
droplet
carrier
drug
inde
antivir
nanoparticl
propos
excel
candid
develop
antivir
therapeut
activ
extend
across
broad
rang
pathogen
although
investig
vivo
effect
differ
nanoparticl
formul
requir
recent
shown
carbon
nanoparticl
capabl
inhibit
antivir
effect
human
cathelicidin
toward
rv
vitro
last
vitro
studi
clinic
trial
suggest
red
seawe
polysaccharid
carrageenan
antivir
activ
rv
vitro
vivo
iotacarrageenan
sulphat
varieti
demonstr
prevent
replic
nasal
epithelium
clinic
trial
examin
effect
iotacarrageenan
contain
nasal
spray
found
patient
found
posit
rv
infect
treat
nasal
spray
demonstr
signific
reduct
durat
symptom
enhanc
resolut
infect
compar
placebo
control
host
defens
peptid
hdp
also
known
antimicrobi
peptid
key
effector
molecul
innat
immun
respons
peptid
found
mani
vertebr
invertebr
organ
display
broad
antimicrobi
potenti
act
directli
virus
bacteria
human
mammal
two
primari
famili
hdp
well
character
term
antimicrobi
activ
cathelicidin
defensin
hdp
express
leukocyt
epitheli
cell
rel
unaffect
modern
drug
resist
mechan
addit
power
direct
antivir
antibacteri
activ
also
demonstr
peptid
possess
immunomodulatori
inflammomodulatori
activ
alter
host
cellular
respons
viral
infect
hdp
repres
excit
opportun
natur
occur
synthet
peptid
deriv
use
novel
therapeut
approach
viral
infect
cathelicidin
well
character
famili
hdp
power
antimicrobi
immunomodulatori
activ
cathelicidin
highli
conserv
famili
peptid
found
number
speci
repres
one
primari
effector
defens
molecul
invad
microorgan
sole
human
cathelicidin
human
cathelicidin
antimicrobi
peptid
kda
activ
form
proteolyt
cleav
primarili
store
specif
granul
neutrophil
cleav
activ
form
also
produc
secret
macrophag
lymphocyt
epitheli
cell
studi
shown
defici
human
lead
increas
suscept
infect
mice
defici
murin
cathelicidin
mcramp
also
display
increas
suscept
bacteri
viral
infect
airway
tract
skin
urinari
tract
gut
contrari
exogen
deliveri
murin
model
offer
enhanc
clearanc
reduc
mortal
lethal
influenza
infect
antimicrobi
properti
cathelicidin
attribut
highli
cation
charg
allow
interact
neg
charg
bacteri
viral
membran
lead
format
pore
hydrophob
help
integr
peptid
microbi
membran
cathelicidin
shown
potent
antivir
activ
number
virus
review
exact
mechan
action
still
fulli
elucid
clear
underli
antivir
mechan
cathelicidin
appear
partli
due
direct
effect
viru
envelop
extens
shown
vitro
studi
murin
cathelicidin
mcramp
shown
abil
damag
viral
envelop
vaccinia
viru
influenza
viru
iav
hsv
also
shown
target
viral
envelop
protein
inhibit
dengu
viru
entri
host
cell
howev
studi
also
reveal
cathelicidin
abil
inactiv
nonenvelop
virus
adenoviru
rv
context
rv
found
optim
inhibit
viru
replic
reach
viru
directli
expos
peptid
prior
infect
cell
howev
studi
viral
pathogen
shown
host
cell
pretreat
delay
treatment
exogen
also
inhibit
rsv
iav
replic
extent
vivo
studi
also
demonstr
abil
modul
inflammatori
respons
viral
infect
inhibit
excess
inflamm
iavinfect
mice
indic
mechan
underpin
cathelicidin
antivir
activ
complex
direct
interact
viru
particl
allow
peptidemedi
damag
bind
viral
envelop
may
key
requir
activ
howev
interact
host
cell
modul
inflammatori
innat
antivir
respons
could
also
critic
import
activ
peptid
other
shown
exogen
vitamin
dmediat
cathelicidin
product
potent
direct
antivir
activ
rv
includ
cathelicidin
mammalian
speci
porcin
cathelicidin
ovin
cathelicidin
indic
antivir
activ
cathelicidin
speciesspecif
human
rv
investig
mechan
underpin
activ
assess
abil
induc
cell
death
rvinfect
airway
epitheli
cell
previous
report
induc
apoptot
cell
death
pseudomona
aeruginosainfect
lung
epitheli
cell
contrast
observ
induc
apoptosi
necrosi
rvinfect
airway
epitheli
cell
addit
direct
antivir
activ
also
shown
abil
modul
inflamm
may
prove
key
properti
develop
therapeut
modul
inflammatori
respons
viral
infect
vitamin
known
posit
effect
bone
miner
calcium
metabol
sever
defici
classic
link
ricket
mount
evid
point
key
immunomodulatori
role
vitamin
link
vitamin
defici
increas
suscept
acut
viral
infect
furthermor
despit
conflict
report
heterogen
within
studi
recent
systemat
review
encompass
particip
random
control
trial
conclud
vitamin
supplement
reduc
risk
acut
respiratori
infect
stronger
protect
effect
patient
baselin
level
nmoll
human
primarili
obtain
vitamin
solar
exposur
diet
solar
ultraviolet
b
radiat
convert
previtamin
rapidli
convert
vitamin
vitamin
skin
diet
convert
circul
serum
use
determin
vitamin
statu
lung
epitheli
cell
immun
cell
convert
circul
inact
activ
form
oh
calcitriol
engag
nuclear
vitamin
receptor
vdr
mediat
myriad
action
reveal
import
health
problem
underscor
possibl
intervent
vitamin
supplement
immedi
consequ
nuclear
vdr
ligat
heterodimer
retinoid
x
receptor
bind
vitamin
respons
element
promot
region
respons
gene
gene
includ
camp
correspond
human
cation
antimicrobi
peptid
kda
hdp
induct
vitamin
report
sever
cell
type
includ
lung
epitheli
cell
relev
calcitriol
oh
deliveri
human
primari
bronchial
epitheli
cell
hpbec
h
prior
infect
prove
suffici
reduc
viral
replic
comparison
untreat
cell
effect
also
observ
cell
cystic
fibrosi
patient
twofold
reduct
viru
importantli
camp
mrna
express
increas
vitamin
exogen
deliveri
recombin
recapitul
antivir
effect
observ
vitamin
deliveri
subsequ
studi
valid
antivir
effect
calcitriol
pretreat
serotyp
reduc
viral
rna
virion
releas
hpbec
two
studi
show
calcitriol
induc
exogen
direct
antivir
effect
rv
activ
conserv
mammal
cathelicidin
complex
physiolog
model
fulli
differenti
hpbec
interfac
use
address
effect
calcitriol
replic
reduct
viral
load
observ
howev
clear
effect
cell
morpholog
replic
note
dose
calcitriol
use
studi
lower
nm
mention
studi
differ
underscor
import
cell
deliveri
system
use
studi
vitamin
effect
regard
daili
deliveri
calcitriol
tablet
form
week
fail
significantli
increas
nasal
concentr
doubleblind
placebocontrol
studi
involv
healthi
asthmat
subject
interestingli
group
report
expos
fulli
differenti
hpbec
proinflammatori
cytokin
prior
vitamin
treatment
lessen
induct
reduc
overal
antimicrobi
effect
vitamin
due
alter
metabol
pathway
observ
indic
work
area
requir
particularli
context
chronic
inflammatori
lung
diseas
find
could
limit
benefit
vitamin
supplement
strategi
upregul
endogen
hdp
product
deliveri
exogen
cathelicidin
synthet
analog
repres
novel
excit
therapeut
strategi
protect
treat
human
rv
infect
therefor
need
investig
mechan
behind
abil
inhibit
viral
infect
establish
antirv
activ
famili
peptid
includ
defensin
understand
small
peptid
oper
could
support
develop
novel
therapeut
strategi
rv
possibl
viral
infect
modul
target
host
molecul
respons
facilit
infect
viral
replic
may
also
provid
valuabl
therapeut
avenu
therapeut
treatment
rv
one
area
interest
focus
upon
innat
antivir
respons
result
broad
rang
protect
infect
attribut
interferon
purif
studi
interferon
found
devoid
inher
antivir
activ
stimul
product
antivir
molecul
led
coin
phrase
antivir
state
upon
recognit
pathogen
cellular
sensor
includ
tlr
rlr
type
ifn
type
iii
ifn
earliest
immun
mediat
produc
review
subsequ
bind
interferon
receptor
induc
express
sever
interferonstimul
gene
result
power
antivir
immunomodulatori
effect
limit
infect
featur
induc
antivir
state
includ
resist
viral
replic
induct
apoptot
cell
death
increas
express
major
histocompat
complex
class
infect
cell
interferon
also
impact
immun
cell
activ
dendrit
cell
dc
macrophag
stimul
nk
cell
enhanc
cytolyt
activ
multifacet
broadspectrum
protect
key
success
antivir
respons
recent
studi
shown
rv
detect
differ
sensor
within
host
cell
compon
capsid
detect
ssrna
genom
detect
dsrna
gener
viral
replic
detect
endosom
rigi
cytosol
constitut
express
lung
epitheli
cell
wherea
rigi
upregul
respons
infect
importantli
gene
silenc
dsrna
sensor
use
sirna
reduc
cytokin
respons
increas
rv
replic
suggest
coordin
role
multipl
sensor
antivir
respons
rv
context
mice
lack
exhibit
higher
load
rna
virus
decreas
product
type
ifn
compar
wildtyp
mice
significantli
case
studi
report
child
harbor
homozyg
missens
mutat
gene
encod
highli
suscept
recurr
lifethreaten
rv
infect
gene
mutat
result
failur
recogn
associ
rv
infect
lead
reduc
ifn
product
therefor
increas
suscept
rv
vitro
studi
shown
exogen
deliveri
ngml
interferon
reduc
viral
copi
hpbec
interestingli
exogen
addit
also
suppress
replic
hpbec
isol
healthi
asthmat
individu
howev
exogen
ifn
deliveri
also
potenti
impact
alreadi
elev
cytokin
level
found
rv
infect
thu
caution
must
exercis
therapeut
strategi
polyinosinicpolycytidyl
acid
commonli
refer
poli
c
dsrna
structur
mimic
intermedi
gener
viral
replic
sens
cytoplasm
rlr
sensor
rigi
poli
c
induc
strong
interferon
respons
prophylact
administr
poli
c
vitro
vivo
enhanc
protect
number
viral
infect
includ
sever
strain
rv
addit
regul
interferon
respons
poli
c
power
induc
proinflammatori
cytokin
chemokin
link
matur
dc
nk
cell
cytotox
virusspecif
tcell
respons
amplif
innat
adapt
immun
provid
protect
rang
virus
includ
influenza
rift
valley
fever
viru
rabi
viru
sarscobv
rsv
data
laboratori
shown
pretreat
bronchial
epitheli
cell
poli
c
substanti
affect
rv
replic
figur
drug
base
poli
c
deriv
develop
broadspectrum
antivir
potenti
adjuv
dctarget
vaccin
poli
c
stabil
polyllysin
carboxymethylcellulos
known
polyiclc
shown
efficaci
virus
influenza
also
test
hiv
vaccin
trial
oncovir
inc
dalton
pharma
servic
canada
pika
newbiom
pika
pte
ltd
singapor
chemic
stabil
analog
poli
c
also
reduc
influenza
viru
load
lung
infect
mice
antivir
effect
hold
promis
treatment
rv
infect
deliveri
poli
c
instanc
lead
increas
bacteri
replic
mycobacterium
tuberculosi
streptococcu
pneumonia
staphylococcu
aureu
impair
clearanc
lung
due
prolong
interferon
signal
given
rv
frequent
associ
increas
secondari
bacteri
infect
especi
individu
chronic
obstruct
pulmonari
diseas
underli
morbid
work
requir
determin
whether
poli
c
stabil
analog
safe
antivir
therapeut
rv
infect
therapeut
strategi
may
target
host
factor
identifi
import
context
rv
replic
exampl
oxysterol
bind
protein
osbp
phosphatidylinositol
iii
identifi
host
protein
involv
picornaviru
replic
studi
focus
upon
chemic
inhibit
panel
aminothiazol
demonstr
potent
inhibit
rv
equal
novel
enviroximelik
compound
well
compound
itraconozol
mention
target
osbp
also
shown
promis
inhibit
viral
replic
furthermor
osbp
act
substrat
protein
kinas
pkd
recent
studi
identifi
pkd
key
molecul
rv
replic
demonstr
pkd
inhibit
profoundli
affect
rv
replic
earli
stage
interestingli
lipidmodifi
enzym
recent
describ
play
role
picornaviru
replic
enhanc
viral
protein
synthesi
note
recent
studi
report
novel
compound
term
show
potent
inhibitori
activ
toward
multipl
strain
rv
nanomolar
concentr
particular
compound
block
viral
replic
target
host
cell
nmyristoyltransferas
requir
assembl
viral
capsid
thu
therapeut
option
target
inhibit
function
modul
enzym
other
involv
viral
protein
synthesi
may
valu
rv
ssrna
genom
contain
within
icosahedr
protein
capsid
compris
four
structur
protein
three
surfac
expos
buri
rvspecif
neutral
antibodi
develop
epitop
found
vp
protein
aim
block
interact
stabil
capsid
prevent
viral
uncoat
caus
conform
chang
capsid
induc
prematur
genom
releas
studi
shown
antibodi
rais
specif
n
terminu
rv
neutral
activ
inde
may
promis
target
therapeut
develop
anoth
approach
develop
antibodi
bind
host
cell
receptor
therebi
block
entri
rv
target
transgen
mice
engin
overexpress
extracellular
domain
human
shown
prevent
entri
two
major
group
rv
reduc
cellular
inflamm
proinflammatori
cytokin
product
viru
load
also
observ
model
howev
target
blockag
receptor
use
minor
group
rv
lowdens
lipoprotein
ldl
receptor
prove
elus
also
case
context
develop
univers
antirv
antibodi
problemat
due
antigen
divers
circul
rv
thu
remain
signific
challeng
associ
identif
new
antigen
variant
fact
around
rv
serotyp
bind
murin
receptor
develop
antibodi
therapi
prevent
treatment
viral
infect
recent
review
sever
antibodi
undergo
preclin
develop
clinic
trial
newli
emerg
viral
pathogen
ebola
well
long
stand
pathogen
influenza
present
licens
antibodi
clinic
use
rv
infect
underscor
need
altern
therapeut
strategi
effect
licens
therapeut
treatment
rv
remain
elus
despit
sever
decad
intens
work
aim
character
activ
wide
rang
natur
occur
synthet
compound
infect
answer
problem
may
lie
manipul
host
cell
respons
view
inhibit
rv
replic
spread
exampl
one
recent
studi
screen
potenti
antivir
structur
subsequ
identifi
analyz
compound
found
interfer
intracellular
pyrimidin
synthesi
pathway
furthermor
addit
virusinfect
cell
induc
elev
express
antivir
gene
lead
inhibit
rv
influenza
rsv
coronaviru
replic
exampl
focus
strategi
could
yield
promis
result
futur
anoth
way
forward
could
use
peptid
abl
act
block
receptor
ldl
essenti
rv
bind
entri
cathelicidin
inactiv
nonenvelop
virus
adenoviru
optim
inhibit
rv
replic
occur
viru
directli
expos
peptid
suggest
peptid
bind
compon
capsid
occur
present
virtual
noth
known
determin
cathelicidin
bind
viral
capsid
full
understand
requir
fine
map
cathelicidin
bind
site
identif
activ
peptid
region
mani
therapeut
describ
herein
investig
decad
challeng
pose
particular
pathogen
thu
far
insurmount
encouragingli
new
wave
antivir
peptid
compound
character
past
year
thu
potenti
develop
novel
effect
treatment
target
rv
infect
may
closer
ever
figur
